NSU Newsroom
SharkBytes
Horizons
This version of NSU News has been archived as of February 28, 2019. To search through archived articles, visit nova.edu/search. To access the new version of NSU News, visit news.nova.edu.
This version of SharkBytes has been archived as of February 28, 2019. To search through archived articles, visit nova.edu/search. To access the new version of SharkBytes, visit sharkbytes.nova.edu.
NSU Research Spotlight: Hossein Omidian, Ph.D.
Hossein Omidian, Ph.D. and Research Team.
Hossein Omidian, Ph.D., professor at NSU’s College of Pharmacy’s Department of Pharmaceutical Sciences, works with his research team in developing technologies (patent-pending) to formulate opioid dosage forms with abuse-deterrent features. These technologies will help prevent drug tampering and abuse, which can increase the speed of drug absorption via smoking, inhaling through the nasal passage, and injection, all of which can cause serious illness or death.
His research interests and expertise include abuse-deterrent formulations (ADFs), oral drug delivery, gastroretentive drug delivery technologies, proof of principle studies, polymers, hydrogels, and pharmaceutical formulations. Omidian holds three issued U.S. patents, 31 U.S. and world patent applications, and 21 invention disclosures in the area of hydrogels for drug delivery and obesity as well as abuse deterrent pharmaceutical formulations. He is an author/co-author of 75 peer-reviewed publications, more than 100 conference presentations, and 25 book chapters and books. He is an associate editor of the Journal of Bioactive and Compatible Polymers and on the editorial board of 20 other pharmaceutical and chemistry journals. Omidian is also a U.S. Pharmacopeial Convention delegate representing the NSU’s College of Pharmacy.
Omidian has received multiple grants [Health Professions Division (HPD), President and Chancellor’s] to continue his research on oral gastric retention technologies, abuse deterrent technologies, and technologies to decrease ethanol absorption into systemic circulation. Since 2013, he has filed 14 invention disclosures with NSU’s Office of Research and Technology Transfer, five provisional patent applications, and one PCT (Patent Cooperation Treaty) with the U.S. Patent and Trademark Office. He also has collaborated with NSU’s College of Dental Medicine to develop tissue engineering scaffolds based on hydrocolloids and synthetic polymers.